Bill Gates Is Not Expecting You To Give Up Meat, Even Though The Planet Could Benefit From It — Here’s Why
In a lecture given last week at the fifth Ramnath Goenka Lecture in India, former Microsoft CEO and…
FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication
William Blair has initiated coverage on Mesoblast Ltd (NASDAQ:MESO) with an Outperform rating and a price target of $8. Mesoblast’s lead product,…
Clene’s Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows
Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…
AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…
AstraZeneca’s Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
In a trial, lung cancer patients treated with AstraZeneca plc’s (NASDAQ:AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the…
The FDA has Cleared Vertex Pharmaceuticals’ Investigational New Drug Application For VX-264, Stem Cell-Derived Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into Vertex-Developed, Immunoprotective Device For Type 1 Diabetes
Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023 to study the safety, tolerability and efficacy of VX-264 in patients with T1D. The company previously received approval from Health Canada
AstraZeneca Announces TAGRISSO Demonstrated Statistically And Clinically Meaningful Improvement In Overall Survival
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival
Reported Late Wednesday March 08, Bionomics Reports Promising Full Results Analysis From PREVAIL Phase 2 Study Of BNC210 Social Anxiety Disorder; PREVAIL Did Not Meet Its Primary Endpoint
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge
Results achieved statistical significance in post-hoc analysis of the full
Reported Late Wednesday March 08, ProMIS Neurosciences Announces FY22 Financial Results And Recent Highlights; Cash And Cash Equivalents Were $5.9M As Of December 31, 2022 Vs $16.9M YoY
Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration
Preclinical data that further characterize ongoing programs, including PMN310, to be presented